TriNetX EHR analysis of 16,569 vitiligo patients versus matched controls demonstrated higher rates of depression, anxiety, panic disorder, insomnia, and nonorganic sexual dysfunction, with slightly ...

Centanafadine XR 280 mg QD significantly reduced AISRS total scores at week 8 versus placebo (LS mean change -18.5 vs -12.6; treatment difference -5.87). Improvement in comorbid anxiety was ...

Zanubrutinib plus rituximab demonstrated a clinically meaningful progression-free survival advantage over bendamustine plus rituximab in previously untreated MCL, with a 43% risk reduction for ...

Broad formulary uptake includes unrestricted access via UnitedHealthcare, Express Scripts, Cigna, Optum Rx, and TRICARE, with prior authorization common among some Blue Cross plans and CVS Caremark.

Payer perspective regarding strategies that can be deployed to help improve the patient/provider experience and utilization of PrEP therapy as prophylaxis against HIV.

FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...

Reconstructed IPD meta-analysis showed chemoimmunotherapy improved OS and PFS versus PD-(L)1 monotherapy within PD-L1–high disease, with consistent findings across multiple analytic approaches and ...

This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...

In SYNCHRONIZE-MASLD (n=218), 84.2% on weekly survodutide 6.0 mg achieved ≥30% relative liver fat reduction versus 24.3% with placebo at week 48. Liver fat normalization occurred in ~61% of ...

Sponsored by Esperion. Newsletter Get the latest industry news, event updates and more from Managed Healthcare Executive.

Cohorts included 1,653 AL, 1,055 ATTRwt-CM, and 59 dual-diagnosis patients; only 53%–66% had any relevant test documented, and just 40%–49% had AL-specific workups. Complete monoclonal protein testing ...